#China #Beijing #Nerivio #Pier 88 Health #Theranica

Nerivio® REN Wearable: A New Era in Migraine Treatment in China

Pier 88 Health, a prominent digital health company, in partnership with Theranica, recently celebrated a significant milestone: the approval of the Nerivio® REN wearable device by the National Medical Products Administration (NMPA) in China. This marks the first instance of a wearable migraine treatment employing Remote Electrical Neuromodulation (REN) technology receiving regulatory approval in the country, a major advancement in pain management and migraine therapy.

What is the Nerivio® REN?

The Nerivio® REN wearable device is a revolutionary tool designed for the acute treatment of migraines. Utilizing gentle electrical pulses delivered to the arm, it activates the brain's natural pain regulation system, providing patients with effective relief from migraine symptoms during an attack. Additionally, when used preventively, it can reduce the frequency of future migraine episodes. This innovative therapy does not involve drugs, needles, or invasive procedures, making it particularly appealing to those hesitant about traditional medication options.

Addressing a Public Health Concern

With an estimated 130 million people in China suffering from migraines and an alarming number of these individuals experiencing the progression from episodic to chronic migraines, there is an urgent need for effective treatments. The reliance on oral medications often comes with issues of accessibility and potential side effects, placing a heavy burden on both patients and healthcare systems. This approval signifies a leap towards providing accessible, patient-empowered solutions that focus on non-invasive care.

A Digital Ecosystem for Migraine Management

Pier 88 Health is not only introducing the Nerivio® REN wearable but is also fostering a comprehensive digital ecosystem tailored for migraine management. This includes digital tools such as TengAI Health, a WeChat-based platform for symptom tracking, and MedLinc, a dedicated mobile application that enables physicians to offer ongoing support to their patients. Incorporating advanced technologies and artificial intelligence, these platforms empower patients to actively participate in their migraine management, enhancing their quality of life.

The Future of Migraine Care

Min Luo, CEO and co-founder of Pier 88 Health, emphasized that this approval sets a new standard for patient-centered migraine treatment in China. The focus is on earlier, drug-free interventions that can significantly lessen the long-term burden of migraine-related disabilities. As more patients gain access to these innovative treatments, the hope is to promote a shift towards more sustainable and holistic approaches to migraine management.

Dr. Xiang Qian, a Clinical Professor of Pain Medicine at Stanford University and Chief Medical Advisor for Pier 88 Health, shared insights into the significance of REN therapy in neuromodulation. He noted the growing evidence supporting the effectiveness of such technologies in pain management, which adds credibility to the deployment of wearable devices like Nerivio in clinical settings.

Global Impact and Scalability

Nerivio’s entry into the Chinese market is part of a broader global rollout, with previous approvals in regions including the U.S., Europe, India, and South Africa. Ronen Jashek, COO and co-founder of Theranica, remarked on the extensive real-world use of Nerivio that underscores its international scalability and potential to reshape migraine management. The initial approval of the device covers adults suffering from acute migraine episodes, with prospects for further expansion to accommodate a wider range of indications and patient demographics.

Conclusion

The launch of the Nerivio® REN wearable in China signals a transformative moment in the realm of migraine treatment. With its innovative approach and digital health integration, this device represents a significant step forward in empowering patients, enhancing care options, and reducing reliance on pharmacological treatments. As awareness of non-drug solutions grows, we can expect a positive shift towards more comprehensive and effective approaches to migraine relief in the future.